First-in-human phase I study of EMB-02, a bispecific antibody targeting PD-1 and LAG-3 in patients with advanced solid tumors
EMB-02 demonstrated a favorable safety profile and early efficacy signals in multiple solid tumors, warranting further development. (NCT04618393).
Authors
- Lu Si (ORCID: https://orcid.org/0000-0002-2123-9761)
- Vinod Ganju (ORCID: https://orcid.org/0000-0003-4713-7752)
- Ki Y. Chung (ORCID: https://orcid.org/0000-0001-6586-2013)
- Shuqi Zeng
- Morteza Aghmesheh (ORCID: https://orcid.org/0000-0003-1664-4743)
- Karen Brewin
- Daphne Day (ORCID: https://orcid.org/0000-0001-8262-2441)
- Lili Mao (ORCID: https://orcid.org/0000-0003-3236-352X)
- Chengjun Jiang (ORCID: https://orcid.org/0000-0001-9297-9399)
- Jun Guo (ORCID: https://orcid.org/0000-0003-1759-0986)
- Fang Ren (ORCID: https://orcid.org/0000-0002-4311-9365)
- Mingfei Zhang (ORCID: https://orcid.org/0000-0002-4663-2404)
- Yonghong Zhu
- Qiaoyang Lu
- Robert J. Hoyer
Institutions
- Prisma Health (US)
- Monash Medical Centre (AU)
- Prince of Wales Hospital (AU)
- Monash Health (AU)
- Ministry of Education (ET)
- Memorial Hospital (US)
Publication Details
- Journal
- British Journal of Cancer
- Published
- 2025-04-15
- DOI
- https://doi.org/10.1038/s41416-025-02990-x
- Citations
- 5
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 5.23